over 2 years ago // Sponsored by International Federation of Pharmaceutical Manufacturers & Associations

With WHO declaring that COVID-19 is no longer a public health emergency of international concern, there is a risk we turn from panic to neglect. IFPMA’s Thomas Cueni argues that we must look at the data and evidence from the COVID-19 response to better prepare for future pandemics.

over 7 years ago // Sponsored by the International Federation of Pharmaceutical Manufacturers & Associations

The International Federation of Pharmaceutical Manufacturers & Associations releases a new report exploring global health progress over the past 50 years, as well as acknowledging industry challenges and areas of unfinished business. Thomas Cueni, IFPMA’s director-general explains why more needs to be done to enhance access to medicines and vaccines.

over 8 years ago // Produced in Collaboration: Healthy Horizons

During the HIV/AIDs epidemic 20 years ago, access to life-saving medicines in developing countries was difficult, due partly to legal battles. Fast forward to today and pharmaceutical companies are now actively engaging in efforts to provide universal health coverage for all. Thomas Cueni, head of IFPMA — International Federation of Pharmaceutical Manufacturers and Associations — explains how the industry is helping to move the needle on health care access.